Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 1/20 | 0.44 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.44 |
| ▸ | MAP4K1 | Q92918 | 12/20 | 0.39 |
| ▸ | CDK9 | P50750 | 1/20 | 0.38 |
| ▸ | SYK | P43405 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.37 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.36 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | FSHR | P23945 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14904853 | 0.83 | GSK3B (0.47) | GSK3BDYRK1AMAP4K1CDK9SYK | |
| SCHEMBL20647996 | 0.82 | GSK3B (0.44) | GSK3BDYRK1ACDK9SYKMAPK1 | |
| SCHEMBL29703975 | 0.82 | GSK3B (0.44) | GSK3BDYRK1ACDK9SYKMAPK1 | |
| SCHEMBL29137922 | 0.82 | GSK3B (0.41) | GSK3BDYRK1AMAP4K1CDK9SYK | |
| SCHEMBL29874548 | 0.77 | GRM2 (0.35) | SYKGRM2 | |
| SCHEMBL14904903 | 0.76 | GSK3B (0.47) | GSK3BDYRK1ACDK9SYKMAPK1 | |
| SCHEMBL20520009 | 0.75 | GSK3B (0.47) | GSK3BDYRK1AMAP4K1CDK9SYK | |
| SCHEMBL29703935 | 0.75 | SCN9A (0.40) | GSK3BDYRK1ACDK9SYKGRM2 | |
| SCHEMBL30636312 | 0.74 | GRM2 (0.35) | SYKGRM2 | |
| SCHEMBL26933292 | 0.74 | GRM2 (0.35) | SYKGRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117062804-A | 1, 3-substituted cyclobutyl derivatives and their use | 诺华股份有限公司 | 2023-11-14 | — | — | CN | disclosed |